Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ArriVent BioPharma, Inc. (AVBP)
NASDAQ:AVBP
ArriVent BioPharma, Inc. (AVBP) Stock Price & Analysis
15 Followers
AVBP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.35 - $25.95
Previous Close$18.27
Volume99.16K
Average Volume (3M)82.82K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$166.36M
Total Debt (Recent Filing)$44.00K
Price to Earnings (P/E)―
Beta0.94
Next Earnings
May 08, 2024EPS Estimate
-$1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.23
Shares Outstanding33,493,750
10 Day Avg. Volume58,187
30 Day Avg. Volume82,823
Standard Deviation0.15
R-Squared0.17
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)-1.38
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-9.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$31.00Price Target Upside66.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
ArriVent BioPharma, Inc. News
PremiumCompany Announcements
ArriVent BioPharma’s Strategic Alliance for Cancer Drug Development
PremiumCompany Announcements
ArriVent BioPharma Welcomes Dr. Hohneker to BoardBulls Say, Bears Say
Bulls Say
Clinical DevelopmentFirmonertinib achieved 79% ORR and a median DOR of 15.2 months, showing potential for best-in-class efficacy and de-risking the phase 3 trial.
Collaboration AgreementArriVent announced a collaboration agreement with Jiangsu Alphamab Biopharmaceuticals to develop and commercialize novel antibody-drug conjugates for treating various cancers.
Financial PerformanceArriVent ended 1Q24 with $317.4M in cash, cash equivalents, and marketable securities, providing an operational runway into 2027 and through multiple clinical data readouts.
Bears Say
Clinical TrialsSlower-than-anticipated enrollment in the Phase 3 FURVENT trial could delay potential drug approvals and revenue.
EarningsQ1 diluted GAAP EPS was significantly lower than analyst estimates, indicating worse-than-expected financial performance.
Stock DilutionPossible long-term dilution risk is a concern for investors, potentially decreasing the value of existing shares.
---
Ownership Overview
27.49% Insiders
8.29% Mutual Funds
55.01% Other Institutional Investors
9.20% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
AVBP FAQ
What was ArriVent BioPharma, Inc.’s price range in the past 12 months?
ArriVent BioPharma, Inc. lowest stock price was $14.35 and its highest was $25.95 in the past 12 months.
What is ArriVent BioPharma, Inc.’s market cap?
Currently, no data Available
When is ArriVent BioPharma, Inc.’s upcoming earnings report date?
ArriVent BioPharma, Inc.’s upcoming earnings report date is May 08, 2024 which is 59 days ago.
How were ArriVent BioPharma, Inc.’s earnings last quarter?
ArriVent BioPharma, Inc. released its earnings results on Mar 28, 2024. The company reported -$5.3 earnings per share for the quarter, missing the consensus estimate of -$0.65 by -$4.65.
Is ArriVent BioPharma, Inc. overvalued?
According to Wall Street analysts ArriVent BioPharma, Inc.’s price is currently Undervalued.
Does ArriVent BioPharma, Inc. pay dividends?
ArriVent BioPharma, Inc. does not currently pay dividends.
What is ArriVent BioPharma, Inc.’s EPS estimate?
ArriVent BioPharma, Inc.’s EPS estimate is -$1.08.
How many shares outstanding does ArriVent BioPharma, Inc. have?
ArriVent BioPharma, Inc. has 33,493,750 shares outstanding.
What happened to ArriVent BioPharma, Inc.’s price movement after its last earnings report?
ArriVent BioPharma, Inc. reported an EPS of -$5.3 in its last earnings report, missing expectations of -$0.65. Following the earnings report the stock price went up 0.638%.
Which hedge fund is a major shareholder of ArriVent BioPharma, Inc.?
Among the largest hedge funds holding ArriVent BioPharma, Inc.’s share is Perceptive Advisors LLC. It holds ArriVent BioPharma, Inc.’s shares valued at 7M.
---
ArriVent BioPharma, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Company Description
ArriVent BioPharma, Inc.
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc.
---
AVBP Stock 12 Month Forecast
Average Price Target
$31.00
▲(66.67% Upside)
Technical Analysis
Best Analysts Covering AVBP
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
+3.87%
reiterated a buy rating last month
Copying Robert Burns's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +3.87% per trade.
---